Zobrazení zdroje stránky Barronkloster3997

raft model. Our work represents a potential strategy for enhancing PDA tumor penetration and immunochemotherapy. Talimogene&nbsp;laherparepvec (T-VEC) is an oncolytic virus based on herpes simplex virus type 1 approved for intralesional treatment of advanced melanoma. In this article, we review the clinical literature on T-VEC for advanced melanoma and provide a practical approach to using T-VEC in the dermatologic surgery and oncology clinic. PubMed was used to conduct a systematic literature review of articles describing the structure, basic science, and clinical and therapeutic properties of T-VEC. The national clinical trials database was also searched for T-VEC clinical trials. Phase I to III clinical trials and early real-world experience have shown the efficacy of T-VEC in advanced melanoma as single or combination therapy with tolerable adverse effects. We conclude that with a standardized clinical approach and training, dermatologists can pave the way in using T-VEC and future oncolytic virus therapies in appropriate clinical scenarios. BACKGROUND Efficacious&nbsp;topical medications for rosacea are needed. FMX103 1.5% is a novel topical minocycline foam that may have therapeutic benefits in treating rosacea while minimizing systemic adverse effects due to its topical route of delivery. OBJECTIVE To determine the efficacy, safety, and tolerability of 12&nbsp;weeks of treatment with FMX103 1.5% topical minocycline foam for papulopustular rosacea. METHODS Two 12-week, phase 3, randomized, multicenter, double-blind, vehicle-controlled, 2-arm studies were performed in patients with moderate to severe papulopustular rosacea. RESULTS Participants who received FMX103 1.5%, versus control individuals treated with vehicle, exhibited a significantly greater reduction in the number of inflammatory lesions (FX2016-11 -17.57 vs -15.65; P&nbsp;=&nbsp;.0031; FX2016-12 -18.54 vs -14.88; P&nbsp; less then &nbsp;.0001) and higher rates of Investigator Global Assessment treatment success (FX2016-11 52.1% vs 43.0%; P&nbsp;=&nbsp;.0273; FX2016-12 49.1% vs 39.0%; P&nbsp;=&nbsp;.0077). No serious treatment-related treatment-emergent adverse events occurred. LIMITATIONS The generalizability of these data from a controlled clinical trial should be examined in a real-world setting. CONCLUSIONS FMX103 1.5% was efficacious for moderate to severe papulopustular rosacea and maintained a favorable safety profile. BACKGROUND Low-dose total skin electron beam therapy (TSEBT) for mycosis fungoides is popular because of reduced toxicity with effective palliation. We condensed TSEBT, reducing visits by half and overall treatment length by one third. OBJECTIVE To determine the efficacy and safety of a novel condensed low-dose TSEBT for mycosis fungoides. METHODS We conducted a cohort study (2014-2018) with a median follow-up of 22.8&nbsp;months. We delivered 12&nbsp;Gy per 6 fractions with the modified Stanford technique, 3 fractions per week, with boosts to shadowed sites at risk between treatments, completing in 2&nbsp;weeks. Primary outcomes included clinical response, duration of and time to response, and toxicity. Secondary outcomes included patient-reported quality of life (pain, pruritus, and Dermatology Life Quality Index) and physician-scored disease burden (body surface area involvement and Modified Skin Weighted Assessment Tool). RESULTS Of 25 patients, stage IB was most common at the time of TSEBT (36%). The overall response rate was 88%. Most common was a near complete response (36%), and complete response was achieved in 6 (24%) patients. The median duration of response was 17.5&nbsp;months (3.5-44.2), and the median time to response was 2&nbsp;months (range, 0.9-4.1). No patients had toxicity of grade 3 or greater. QOL and disease burden showed significant benefit after TSEBT (P&nbsp; less then &nbsp;.001). LIMITATIONS Cohort study with limited sample size. CONCLUSIONS Condensed, low-dose TSEBT has favorable outcomes and toxicity with logistical convenience. BACKGROUND The current standard in the serological diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIPTM mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence (IF). METHODS Sera from 749 consecutive, prospectively recruited, direct IF positive AIBD patients from 13 international study centers were analyzed independently and blinded using (i) a BIOCHIPTM mosaic including primate esophagus, salt-split skin, recombinant BP180 NC16A and gliadin GAF3x as well as HEK293 cells expressing recombinant desmoglein1, desmoglein3, type VII collagen, and BP230 C-terminus and (ii) the conventional multistep approach of the Department of Dermatology, University of Lübeck. RESULTS In 731 of 749 sera (97.6%) specific autoantibodies could be detected using the BIOCHIPTM mosaic, similar to the conventional procedure (725 cases, 96.8%). Cohens κ for both serological approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the two approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIPTM mosaic. LIMITATIONS Laminin 332 and laminin γ1 are not represented on the BIOCHIPTM mosaic. CONCLUSIONS The BIOCHIPTM mosaic is a standardized, time- and serum-saving approach that further facilitates the serological diagnosis of AIBD. BACKGROUND In&nbsp;instances of suspected cutaneous infection, the standard of care includes obtaining skin biopsy specimens for histology and tissue culture. Few studies have compared the clinical utility of each test. OBJECTIVE To assess the concordance of results between tissue culture and histology, as well as the clinicopathologic features that may influence the diagnostic yield of each test. METHODS A retrospective review of all patients who underwent skin biopsy for histology and tissue culture at New York University from 2013 through 2018. RESULTS Of 179 patients, 10% had positive concordance, 21% had positive tissue culture only, and 7% had positive histology only. [https://www.selleckchem.com/products/danirixin.html GSK1325756 ic50] We calculated a kappa correlation coefficient of 0.25 between histology and tissue culture (reference, 0.21-0.39 indicates minimal agreement). Histology exhibited higher sensitivity in detecting fungi, whereas tissue culture was more sensitive in identifying Gram-negative bacteria. Antimicrobial use before biopsy led to significantly fewer positive cultures (37.